Analyst before Coloplast's 2025 strategy: High growth, increased prices and more clinical studies
When Coloplast unveils its new long-term strategy Tuesday, analyst Niels Granholm-Leth expects to see continued high growth targets, to be achieved through increased prices and more clinical research.
BY KEVIN GRØNNEMANN, TRANSLATED BY IDA JACOBSEN
Tuesday, it will become evident for both employees, investors, analysts and competitors how Coloplast strives to develop over the coming five years, when the company's executive management presents a new long-term 2025 strategy.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
